secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-04-10T23:59:59+00:00
Accession:  0001104659-26-041584
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio prices $10M underwritten offering of common stock and warrants
--------------------------------------------------------------------------

- Pricing of 5,263,156 shares and 5,263,156 warrants at $1.90 per unit, gross proceeds ~$10M.
- Warrants exercisable at $2.50/share, beginning 6 months after issuance, expiring 5.5 years from issue.
- Net proceeds to fund continued clinical development of buntanetap in Phase 3 Alzheimer's study and for working capital.
- Offering expected to close on April 10, 2026; Canaccord Genuity sole bookrunner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926041584/0001104659-26-041584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926041584/tm2611267d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-041584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer